Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.
about
A Blueprint for HIV Vaccine DiscoveryAntibodies against viruses: passive and active immunizationSupersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccineNeutralizing and other antiviral antibodies in HIV-1 infection and vaccination.Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsAntibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120.Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibilityThe highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions.Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralizationEstimating the stoichiometry of human immunodeficiency virus entryHIV-host interactome revealed directly from infected cells.The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regionsModeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies.Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsNeutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotypeBroadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.The V4 and V5 Variable Loops of HIV-1 Envelope Glycoprotein Are Tolerant to Insertion of Green Fluorescent Protein and Are Useful Targets for Labeling.Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes.Comparison of Uncleaved and Mature Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimers.
P2860
Q26829865-186BB3D7-A23F-4B8A-96D9-1FEC06AE9CBAQ27489392-3C78D818-CB94-4B1F-AD10-D68B9CD8051CQ27678306-6FE82C92-16C4-4362-8CB9-DA0DD40971C6Q30358769-5884B293-B07E-4838-B3F3-BEFB2C26C800Q34064787-B989E5A6-7906-4437-B763-17BB45E02336Q34157802-2BCDE8E1-3947-4455-92FB-FD83C08476FAQ35208657-435BAC6D-4EBF-4F75-836D-0C0A2166FB44Q36083337-902F4222-E153-4BD0-9ABE-FCB4E3EB8F58Q36172128-B9731234-9E8E-4110-819F-F4BCC1050B31Q36404752-360A83D7-C60B-42A3-8AE6-18B12FD423C7Q36559735-6F6F94C0-D16F-4FA0-BE70-FE1B413B39E7Q36607016-2DFC8127-364D-48CD-B6E9-2E0197816202Q36837815-0B33CE0F-7757-407A-ADA9-B9ECDDB2D822Q37051613-31C9199C-A2DC-46D1-8981-46896C0CD4DAQ37055800-20449E02-08D5-4D64-B1FE-153EC4607734Q37099851-B297E7A6-8929-4C2D-A59F-C2FBD4F4B529Q37419199-86EF12DF-3AB2-4CA7-BA49-4F242B99C1A0Q38897259-73D9A418-5A9E-46F1-BE51-9F6084E63B99Q39177719-D6FCD0CD-6BEF-4EC4-8175-CF88684B49F9Q39454698-F03C5927-2294-4453-9843-9327CDABB37BQ39704592-C7D28B61-88A7-46F1-A193-F8B2AE958E1AQ39843176-4DF98F68-9DBC-4DFF-A5D3-4649D4AEBB96Q40679052-20103F03-7C06-43A9-AE5C-282BF71D555AQ41287677-7B1C4E44-CFE2-41D3-9BDD-CD9D0D25AC5EQ41967451-846948C6-611F-433A-9F18-241ECFAD826DQ48133582-87ABF38A-DCFD-4775-8840-AD4411CD2074Q52721542-AA4BD949-EFAF-4460-BC95-B60D49FFED97
P2860
Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Antibody binding is a dominant ...... y virus type 1 neutralization.
@en
Antibody binding is a dominant ...... y virus type 1 neutralization.
@nl
type
label
Antibody binding is a dominant ...... y virus type 1 neutralization.
@en
Antibody binding is a dominant ...... y virus type 1 neutralization.
@nl
prefLabel
Antibody binding is a dominant ...... y virus type 1 neutralization.
@en
Antibody binding is a dominant ...... y virus type 1 neutralization.
@nl
P2093
P2860
P356
P1433
P1476
Antibody binding is a dominant ...... y virus type 1 neutralization.
@en
P2093
Inna Lipchina
Irwin Chaiken
Simon Cocklin
Xinzhen Yang
P2860
P304
11404-11408
P356
10.1128/JVI.01102-06
P407
P577
2006-09-06T00:00:00Z